What price target do analysts set for Quest Diagnostics'stock?
What price target have analysts set for DGX? 10 Wall Street analysts have issued 1-year price objectives for Quest Diagnostics' shares. Their forecasts range from $137.00 to $181.00. On average, they anticipate Quest Diagnostics' stock price to reach $160.70 in the next year. This suggests that the stock has a possible downside of 4.6%.
What is the ticker symbol for Quest Diagnostics?
Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." Who are Quest Diagnostics' major shareholders? Quest Diagnostics' stock is owned by many different institutional and retail investors.
Is Quest Diagnostics'downside down 4% from current price?
According to analysts' consensus price target of $160.70, Quest Diagnostics has a forecasted downside of 4.7% from its current price of $168.61. Quest Diagnostics has only been the subject of 3 research reports in the past 90 days. Quest Diagnostics has received 497 “outperform” votes. (Add your “outperform” vote.)
Who bought DGX stock last quarter?
DGX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Schroder Investment Management Group, Robeco Institutional Asset Management B.V., O Shaughnessy Asset Management LLC, Skandinaviska Enskilda Banken AB publ , and Citadel Advisors LLC.
Short Interest ()
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
Per-Share Earnings, Actuals and Estimates
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet.
What is the dividend payout ratio of quest diagnostics?
Quest Diagnostics does not yet have a strong track record of dividend growth. The dividend payout ratio of Quest Diagnostics is 22.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.04% next year.
What is quest diagnostics?
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
When will quest diagnostics repurchase?
Quest Diagnostics announced that its board has authorized a share repurchase program on Thursday, February 4th 2021, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor.
